JP2010514409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514409A5 JP2010514409A5 JP2009515770A JP2009515770A JP2010514409A5 JP 2010514409 A5 JP2010514409 A5 JP 2010514409A5 JP 2009515770 A JP2009515770 A JP 2009515770A JP 2009515770 A JP2009515770 A JP 2009515770A JP 2010514409 A5 JP2010514409 A5 JP 2010514409A5
- Authority
- JP
- Japan
- Prior art keywords
- cytokine
- agent
- tumor
- apoptotic
- expressing tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 102000004127 Cytokines Human genes 0.000 claims 17
- 108090000695 Cytokines Proteins 0.000 claims 17
- 238000000034 method Methods 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 102000004388 Interleukin-4 Human genes 0.000 claims 6
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 230000002424 anti-apoptotic effect Effects 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 230000000861 pro-apoptotic effect Effects 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 230000003472 neutralizing effect Effects 0.000 claims 4
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 3
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 230000000970 DNA cross-linking effect Effects 0.000 claims 1
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002687 intercalation Effects 0.000 claims 1
- 238000009830 intercalation Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000000007 protein synthesis inhibitor Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06012754 | 2006-06-21 | ||
| PCT/EP2007/005480 WO2007147600A2 (en) | 2006-06-21 | 2007-06-21 | Differential il-4 and/or il-10 cytokine expression in human cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514409A JP2010514409A (ja) | 2010-05-06 |
| JP2010514409A5 true JP2010514409A5 (https=) | 2010-06-17 |
Family
ID=38359749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515770A Pending JP2010514409A (ja) | 2006-06-21 | 2007-06-21 | ヒトの癌における鑑別式サイトカイン発現 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090324616A1 (https=) |
| EP (1) | EP2041576B1 (https=) |
| JP (1) | JP2010514409A (https=) |
| CN (1) | CN101529253A (https=) |
| AT (1) | ATE520032T1 (https=) |
| AU (1) | AU2007263265A1 (https=) |
| BR (1) | BRPI0713484A2 (https=) |
| CA (1) | CA2656379A1 (https=) |
| DK (1) | DK2041576T3 (https=) |
| ES (1) | ES2371287T3 (https=) |
| RU (1) | RU2009101783A (https=) |
| WO (1) | WO2007147600A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2646626A1 (en) * | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Antibody specific for human il-4 for the treatment of cancer |
| US20100086515A1 (en) * | 2006-07-06 | 2010-04-08 | Apogenix Gmbh | Human il-4 muteins in cancer therapy |
| EP3409686B1 (en) * | 2012-07-18 | 2022-04-13 | Apogenix AG | Composition comprising a mixture of cd95-fc isoforms |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| AU2015335607B2 (en) * | 2014-10-24 | 2020-04-23 | Calidi Biotherapeutics (Nevada), Inc. | Combination immunotherapy approach for treatment of cancer |
| CN108135996B (zh) | 2015-08-11 | 2022-06-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EA201892260A1 (ru) | 2016-04-07 | 2019-03-29 | Дзе Джонс Хопкинс Юниверсити | Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти |
| EP4053557A1 (en) * | 2016-11-24 | 2022-09-07 | Huvet Bio, Inc. | Il-29 as a marker for a pancreatic disease |
| CN111051349A (zh) * | 2017-09-06 | 2020-04-21 | 弗雷德哈钦森癌症研究中心 | Strep-tag特异性嵌合受体及其用途 |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643427B2 (en) * | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| DE4137333A1 (de) * | 1991-11-13 | 1993-05-19 | W Prof Dr Sebald | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
| US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| WO1995007301A1 (en) | 1993-09-07 | 1995-03-16 | Smithkline Beecham Corporation | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
| DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
| AU686816B2 (en) * | 1994-07-05 | 1998-02-12 | Steeno Research Group A/S | Immunomodulators |
| HUT76369A (en) * | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| US20030124125A1 (en) * | 1996-04-05 | 2003-07-03 | South Alabama Medical Science Foundation | Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10 |
| US6028176A (en) * | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| CA2309598A1 (en) * | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung disease |
| JPH11312463A (ja) * | 1998-04-28 | 1999-11-09 | Hitachi Ltd | 配線基板およびそれを用いたガス放電型表示装置 |
| WO2001074388A1 (en) * | 2000-03-31 | 2001-10-11 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| AU2001273413A1 (en) * | 2000-07-12 | 2002-01-21 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
| US20040023338A1 (en) * | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-4 mutein proteins, antibodies, compositions, methods and uses |
| CA2464695A1 (en) * | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| EP1824886B1 (en) * | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
| US20070122855A1 (en) * | 2005-11-28 | 2007-05-31 | Targetgen Inc. | Methods for diagnosing hepatocellular carcinoma |
| CA2646626A1 (en) * | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Antibody specific for human il-4 for the treatment of cancer |
| US20100086515A1 (en) * | 2006-07-06 | 2010-04-08 | Apogenix Gmbh | Human il-4 muteins in cancer therapy |
-
2007
- 2007-06-21 WO PCT/EP2007/005480 patent/WO2007147600A2/en not_active Ceased
- 2007-06-21 CA CA002656379A patent/CA2656379A1/en not_active Abandoned
- 2007-06-21 CN CNA2007800295788A patent/CN101529253A/zh active Pending
- 2007-06-21 JP JP2009515770A patent/JP2010514409A/ja active Pending
- 2007-06-21 ES ES07764767T patent/ES2371287T3/es active Active
- 2007-06-21 AT AT07764767T patent/ATE520032T1/de not_active IP Right Cessation
- 2007-06-21 US US12/306,070 patent/US20090324616A1/en not_active Abandoned
- 2007-06-21 EP EP07764767A patent/EP2041576B1/en active Active
- 2007-06-21 DK DK07764767.5T patent/DK2041576T3/da active
- 2007-06-21 BR BRPI0713484-3A patent/BRPI0713484A2/pt not_active IP Right Cessation
- 2007-06-21 RU RU2009101783/15A patent/RU2009101783A/ru not_active Application Discontinuation
- 2007-06-21 AU AU2007263265A patent/AU2007263265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514409A5 (https=) | ||
| Kanwar et al. | Survivin signaling in clinical oncology: a multifaceted dragon | |
| Visal et al. | Circulating tumour cells in the-omics era: how far are we from achieving the ‘singularity’? | |
| Ding et al. | Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy | |
| Giménez‐Bonafé et al. | YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity | |
| Li et al. | Functional and therapeutic significance of tumor-associated macrophages in colorectal cancer | |
| Toh et al. | The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy | |
| RU2009101783A (ru) | Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека | |
| Patsalias et al. | Personalized medicine: Stem cells in colorectal cancer treatment | |
| Ji et al. | Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy | |
| Sozucan et al. | TRP genes family expression in colorectal cancer | |
| Lue et al. | Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma | |
| JP2016536568A5 (https=) | ||
| JP2018508532A5 (https=) | ||
| de Nonneville et al. | Sacituzumab govitecan in triple-negative breast cancer | |
| Cybulski et al. | Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer | |
| Ramirez-Torres et al. | Quantitative proteomic analysis of cervical cancer tissues identifies proteins associated with cancer progression | |
| Li et al. | Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer | |
| Kuo et al. | Tumor-associated stroma shapes the spatial tumor immune microenvironment of primary Ewing sarcomas | |
| Luo et al. | Alpha fetoprotein (AFP)-producing gastric cancer: clinicopathological features and treatment strategies | |
| Tian et al. | Identification of four key prognostic genes and three potential drugs in human papillomavirus negative head and neck squamous cell carcinoma | |
| Nelson et al. | An increasingly important therapeutic target: Part 2 Distribution of HER2/neu Overexpression and Gene Amplification by Organ, Tumor Site and Histology | |
| Al-Shuneigat et al. | Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study | |
| Momoi et al. | Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution | |
| Gui et al. | Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial |